Luminex (LMNX) Downgraded by ValuEngine to Hold
Several other analysts have also commented on the company. William Blair reissued a “market perform” rating on shares of Luminex in a report on Tuesday, May 7th. BidaskClub raised Luminex from a “sell” rating to a “hold” rating in a report on Tuesday, May 7th. Finally, Zacks Investment Research lowered Luminex from a “hold” rating to a “sell” rating in a report on Monday, April 8th. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $31.33.
Shares of LMNX opened at $21.54 on Friday. The company has a current ratio of 3.99, a quick ratio of 2.70 and a debt-to-equity ratio of 0.04. Luminex has a 12 month low of $20.40 and a 12 month high of $35.37. The company has a market capitalization of $964.76 million, a price-to-earnings ratio of 44.88, a price-to-earnings-growth ratio of 19.86 and a beta of 0.75.
A number of institutional investors and hedge funds have recently modified their holdings of the business. NumerixS Investment Technologies Inc acquired a new stake in shares of Luminex in the fourth quarter worth approximately $39,000. Quantamental Technologies LLC acquired a new stake in shares of Luminex in the fourth quarter worth approximately $100,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in shares of Luminex in the fourth quarter worth approximately $100,000. Amundi Pioneer Asset Management Inc. boosted its stake in shares of Luminex by 32.4% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 4,500 shares of the medical instruments supplier’s stock worth $104,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Meeder Asset Management Inc. boosted its stake in shares of Luminex by 11.1% in the first quarter. Meeder Asset Management Inc. now owns 4,925 shares of the medical instruments supplier’s stock worth $113,000 after acquiring an additional 491 shares during the last quarter. 85.74% of the stock is currently owned by institutional investors.
Luminex Company Profile
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.
Further Reading: What is a stock split?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.